EP2069376A4 - Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions - Google Patents

Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Info

Publication number
EP2069376A4
EP2069376A4 EP07861332.0A EP07861332A EP2069376A4 EP 2069376 A4 EP2069376 A4 EP 2069376A4 EP 07861332 A EP07861332 A EP 07861332A EP 2069376 A4 EP2069376 A4 EP 2069376A4
Authority
EP
European Patent Office
Prior art keywords
peptide
nucleic acid
influenza virus
immune responses
cellular immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07861332.0A
Other languages
German (de)
French (fr)
Other versions
EP2069376A2 (en
Inventor
Jeffery L Alexander
Scott F Southwood
Pamuk A Bisel
Mark J Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmexa Inc
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Publication of EP2069376A2 publication Critical patent/EP2069376A2/en
Publication of EP2069376A4 publication Critical patent/EP2069376A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
EP07861332.0A 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions Withdrawn EP2069376A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83211206P 2006-07-21 2006-07-21
PCT/US2007/016529 WO2008039267A2 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Publications (2)

Publication Number Publication Date
EP2069376A2 EP2069376A2 (en) 2009-06-17
EP2069376A4 true EP2069376A4 (en) 2013-10-16

Family

ID=39230737

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07861332.0A Withdrawn EP2069376A4 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Country Status (4)

Country Link
EP (1) EP2069376A4 (en)
AU (1) AU2007300663A1 (en)
CA (1) CA2658559A1 (en)
WO (1) WO2008039267A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363240B (en) * 2007-06-25 2019-03-15 The Administrators Of The Tulane Educational Fund Influenza inhibiting compositions and methods.
US8747861B2 (en) * 2007-08-02 2014-06-10 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
EP2296688A2 (en) * 2007-10-26 2011-03-23 Glykos Finland Oy Peptide vaccine for influenza virus
FI20080333A0 (en) * 2008-05-02 2008-05-02 Glykos Finland Oy Influenza virus nucleic acids and peptides
BRPI0822947B1 (en) * 2008-11-19 2018-09-18 Laboratorio Avi Mex S A De Cv recombinant vaccine.
US8282938B2 (en) * 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
US20100310591A1 (en) * 2009-01-28 2010-12-09 Robert Humphreys Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
CN101792745B (en) 2009-02-04 2014-09-17 中国科学院生物物理研究所 Expression and purification of influenza virus polymerase PA N-terminal polypeptide and crystal structure thereof
CN101565455B (en) * 2009-05-25 2012-03-14 中国科学院微生物研究所 CTL epitope polypeptides of bird flu H5N1 virus and applications thereof
EP2437779B1 (en) * 2009-06-01 2016-10-26 Her Majesty The Queen In Right of Canada as represented by The Minister of Health Reagents and methods for detecting influenza virus proteins
WO2011014794A1 (en) 2009-07-31 2011-02-03 Paxvax, Inc. Adenoviral-based vectors
US9265822B2 (en) * 2009-09-30 2016-02-23 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
CN102153621B (en) * 2010-02-12 2014-07-02 广东省疾病预防控制中心 B-cell epitope of NA-protein for new influenza A (H1N1) and application thereof
CN102892778B (en) * 2010-02-19 2018-06-08 列日大学 For treating polynucleotides, albumen and the transgenic animals of the disease of influenza A virus induction, the modified Mx albumen of coding
WO2011138032A2 (en) * 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013059403A1 (en) * 2011-10-19 2013-04-25 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of influenza virus infection
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
MX2015008847A (en) * 2013-01-10 2015-10-30 Novartis Ag Influenza virus immunogenic compositions and uses thereof.
CN103333224B (en) * 2013-05-10 2015-03-25 中国农业科学院哈尔滨兽医研究所 Avian influenza virus NS1 protein B cell epitope polypeptide and applications thereof
WO2015186721A1 (en) * 2014-06-03 2015-12-10 国立研究開発法人農業・食品産業技術総合研究機構 Antibody or antibody fragment including variable region thereof, antigen polypeptide, and uses thereof
CA3048448A1 (en) 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines
CN106589105B (en) * 2017-01-23 2020-09-15 中国医科大学 HLA-A2-restricted ECM 1-specific CTL epitope peptide and application thereof
US11517617B2 (en) 2017-09-08 2022-12-06 The University Of Melbourne Methods and compositions for preventing influenza infection
US20220118077A1 (en) * 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
JP2023530134A (en) * 2020-06-19 2023-07-13 インターベット インターナショナル ベー． フェー． A swine influenza A virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding separate neuraminidase antigens of the virus
EP4168428A1 (en) * 2020-06-19 2023-04-26 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages
US20230270838A1 (en) * 2020-08-02 2023-08-31 Richard Ascione Vaccine compositions for influenza viruses and methods of use
EP4204445A2 (en) * 2020-08-25 2023-07-05 Genentech, Inc. Assays and reagents for characterization of mhci peptide binding
CN116410271A (en) * 2023-03-13 2023-07-11 华南农业大学 H5N1 subtype AIV MHC B1 restricted T cell epitope peptide and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060153871A1 (en) * 2005-01-11 2006-07-13 Olsen Christopher W H3 equine influenza A virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060153871A1 (en) * 2005-01-11 2006-07-13 Olsen Christopher W H3 equine influenza A virus

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALEXANDER J ET AL: "Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 71, no. 5, 1 May 2010 (2010-05-01), pages 468 - 474, XP027006096, ISSN: 0198-8859, [retrieved on 20100310] *
EBERL GERARD ET AL: "Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 11, 1996, pages 2709 - 2716, XP055244817, ISSN: 0014-2980 *
EPSTEIN SUZANNE L ET AL: "DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice", EMERGING INFECTIOUS DISEASES, vol. 8, no. 8, August 2002 (2002-08-01), pages 796 - 801, XP002712185, ISSN: 1080-6040 *
FRUCI D ET AL: "Anchor residue motifs of HLA class I-binding peptides analysed by the direct binding of synthetic peptides to HLA class I alpha chains", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 36, no. 1, 1 January 1993 (1993-01-01), pages 67, XP023851425, ISSN: 0198-8859, [retrieved on 19930101], DOI: 10.1016/0198-8859(93)90104-9 *
GIANFRANI C ET AL: "Human memory CTL response specific for influenza A virus is broad and multispecific", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 61, no. 5, 1 May 2000 (2000-05-01), pages 438 - 452, XP002492007, ISSN: 0198-8859, DOI: 10.1016/S0198-8859(00)00105-1 *
GUERCIO DEL M-F ET AL: "BINDING OF A PEPTIDE ANTIGEN TO MULTIPLE HLA ALLELES ALLOWS DEFINITION OF AN A2-LIKE SUPERTYPE", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 154, 1 January 1995 (1995-01-01), pages 685 - 693, XP002055570, ISSN: 0022-1767 *
ISHIOKA G Y ET AL: "UTILIZATION OF MHC CLASS I TRANSGENIC MICE FOR DEVELOPMENT OF MINIGENE DNA VACCINES ENCODING MULTIPLE HLA-RESTRICTED CTL EPITOPES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 162, no. 7, 1 April 1999 (1999-04-01), pages 3915 - 3925, XP000872894, ISSN: 0022-1767 *
KUBO R T ET AL: "DEFINITION OF SPECIFIC PEPTIDE MOTIFS FOR FOUR MAJOR HLA-A ALLELES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 152, no. 8, 1 January 1994 (1994-01-01), pages 3913 - 3924, XP002936662, ISSN: 0022-1767 *
LIVINGSTON B D ET AL: "Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines", VACCINE, ELSEVIER LTD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4652 - 4660, XP004303157, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(01)00233-X *
SIDNEY J ET AL: "SPECIFICITY AND DEGENERACY IN PEPTIDE BINDING TO HLA-B7-LIKE CLASS I MOLECULES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 157, no. 8, 15 October 1996 (1996-10-15), pages 3480 - 3490, XP002055572, ISSN: 0022-1767 *
THRELKELD S C ET AL: "Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 AUG 1997, vol. 159, no. 4, 15 August 1997 (1997-08-15), pages 1648 - 1657, XP002712184, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2007300663A1 (en) 2008-04-03
WO2008039267A2 (en) 2008-04-03
WO2008039267A3 (en) 2008-12-31
EP2069376A2 (en) 2009-06-17
CA2658559A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
EP2069376A4 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP2023952A4 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP1732598A4 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
IL239023A0 (en) Neutralizing antibodies to influenza viruses
PL2066339T3 (en) Compositions and methods of enhancing immune responses
EP2442829A4 (en) Structured viral peptide compositions and methods of use
PL1976559T3 (en) Influenza vaccines containing hemagglutinin and matrix proteins
BRPI1012811A2 (en) herpes simplex virus type 2 vaccines: compositions and methods for obtaining an immune response
EP2089053A4 (en) Hpv antigen fusion protein vaccine compositions and uses thereof
EP2414545A4 (en) Nucleic acid preparation compositions and methods
KR101790354B9 (en) 32 human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
IL215451A (en) Antigenic constructs comprising an antigenic peptide of the tau protein and pharmaceutical compositions comprising same
EP1984405A4 (en) Influenza antigens, vaccine compositions, and related methods
IL209136A (en) Compositions of peptides and processes of preparation thereof
HK1223968A1 (en) Rabies virus and compositions and methods thereof
FI20060946A0 (en) Influenza virus nucleic acids and peptides
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
HK1123055A1 (en) Hepatitis c virus nucleic acid vaccine
IL215955A (en) Uracyl spirooxetane nucleosides, compositions comprising them and uses thereof as hcv inhibitors
HK1112846A1 (en) Canine influenza virus and related compositions and methods of use
EP1885173A4 (en) Chloroplasts engineered to express pharmaceutical proteins
IL212545A (en) Isolated antibodies binding tlr3 and pharmaceutical compositions comprising them
IL213189A0 (en) Recombinant avian influenza vaccine and uses thereof
BRPI1006863A2 (en) vaccine and purified plasmodium compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20090630

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135403

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20130917

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/005 20060101ALI20130906BHEP

Ipc: C07H 21/02 20060101AFI20130906BHEP

17Q First examination report despatched

Effective date: 20160201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160614

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135403

Country of ref document: HK